The first quarter of this year has seen a great deal of volatility in the equity markets. The S&P 500 fell into correction territory before rising again after first soaring to all-time highs. Concerns about high valuations, uncertainties about economic growth related to the Middle East conflict, and increasing inflation pressures brought on by rising energy prices have all contributed to this unrest. Following years of significant gains, investors have started to rotate out of large-cap technology equities.

John Stoltzfus, chief investment strategist at Oppenheimer, claims that rather than a total retreat from technology, this change represents a more comprehensive diversification plan. Rather, in order to balance exposure, investors are taking profits and moving wealth across sectors.

The healthcare industry, however, has found it difficult to gain from this rotation. The S&P 500 healthcare sector is down almost 4% for the year, while the overall index is flat, despite the fact that it is usually seen as a defensive move. Due to post-COVID earnings normalization and policy-related valuation pressures, this downturn has persisted over the last three years. Despite the fact that healthcare has trailed in earnings growth over the last five years, JPMorgan analysts believe things may be getting better, pointing out that recent stabilization and projections imply the worst may be behind us.

Increasing merger and acquisition activity is supporting improved fundamentals as companies look to strengthen their pipelines. In this context, low-priced healthcare penny stocks are gaining attention, particularly when they are backed by insider acquisitions. Insider purchases are frequently seen as strong indications, particularly in an industry where clinical data, market sentiment, and regulatory changes have a significant impact on stock performance.

This viewpoint is shared by institutional investors. Healthcare is highlighted as an appealing entry opportunity by strategies that emphasize substantial insider buying in addition to strong fundamentals, good earnings revisions, and innovative drug research. This opinion is supported by Deloitte’s February 16, 2026, Global Health Care Outlook, which depicts a struggling yet changing sector. Healthcare offers both short-term difficulty and attractive long-term growth potential, with over 70% of non-US executives anticipating increased revenues and profits and AI and digital tools gaining traction despite early adoption problems.

With that said, let’s look at the best healthcare stocks.

15 States with the Best Healthcare in the US

Our Methodology

For our methodology, we screened for stocks with at least 15% three-year EPS growth and positive upside potential. From this filtered list, we selected the top 10 stocks based on recent news and developments, ranking them in ascending order by the total number of hedge fund holdings as of Q4 2025, according to the Insider Monkey database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Here is our list of the 10 best healthcare stocks to buy and hold for 3 years.

10. Grifols, S.A. (NASDAQ:GRFS)

Number of Hedge Fund Holders: 15

Grifols, S.A. (NASDAQ:GRFS) is one of the best healthcare stocks on this list.

TheFly reported on April 2 that CBC News reported that Health Canada introduced new regulatory conditions on GRFS’ paid plasma collection centers nationwide after repeated inspection failures revealed ongoing operational issues. These included gaps in donor screening, inadequate staff training, and non-compliance with standard procedures. The measures will remain until the company demonstrates consistent adherence to regulatory requirements.

Separately, on April 13, Grifols, S.A. (NASDAQ:GRFS) announced plans to repurchase €500 million of its 7.5% senior secured notes maturing in 2030 as part of efforts to lower borrowing costs and reinforce its financial position. The move targets the reduction of its most expensive debt and aligns with broader refinancing initiatives. The company recently completed a strong loan syndication, including an expanded Term Loan B of about €3 billion and a $2 billion revolving credit facility, supported by institutional investors.

Following the expected completion of this refinancing, GRFS will not face significant debt maturities until late 2028. These actions are designed to decrease overall debt levels, reduce interest expenses, and improve the company’s debt timeline while preserving liquidity. The planned note redemption is contingent upon the closing of the new financing arrangements and the successful restructuring of debt obligations due in 2027.

Grifols, S.A. (NASDAQ:GRFS) is a global healthcare company specializing in plasma-derived therapies and transfusion medicine. It develops and manufactures biologics to treat chronic and rare diseases, operating an extensive plasma collection network and advanced production facilities worldwide.

9. Community Health Systems, Inc. (NYSE:CYH)

Number of Hedge Fund Holders: 29

Community Health Systems, Inc. (NYSE:CYH) is one of the best healthcare stocks to invest in.

TheFly reported on April 12 that Truist Securities revised its outlook on CYH, reducing its price target to $3.50 from $4.00 while maintaining a Hold rating. The adjustment was made within a broader healthcare services research update ahead of the upcoming first-quarter results.

The firm highlighted generally positive industry conditions, supported by steady demand, supportive long-term trends, and a more stable reimbursement environment, including recent Medicare Advantage policy updates viewed as favorable. It also noted that the sector remains attractive due to its domestic focus, scale advantages, and defensive characteristics. Additional support comes from strong cash generation and financial flexibility, which allows continued investment, mergers and acquisitions, and shareholder-focused strategies, including buybacks and other returns.

Separately, earlier on April 1, Community Health Systems, Inc. (NYSE:CYH) finalized the sale of Crestwood Medical Center, a 180-bed hospital in Huntsville, Alabama, along with its related outpatient facilities and physician practices. The assets were transferred to Huntsville Hospital Health System in a transaction valued at $459 million before expenses.

The deal was initially announced in January 2026 and represents part of the company’s broader plan to streamline its portfolio through selective asset sales. This divestiture aligns with previously discussed strategies to optimize operations and reallocate resources, as outlined during the company’s recent earnings discussions and subsequent public updates.

Community Health Systems, Inc. (NYSE:CYH) is one of the largest publicly traded hospital operators in the U.S., providing acute care services through a network of hospitals and outpatient facilities. It focuses on delivering accessible healthcare in non-urban and regional communities.

5. Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Number of Hedge Fund Holders: 41

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the best healthcare stocks on this list.

TheFly reported on April 13 that Leerink Partners began coverage of ZBH with a Market Perform rating and a $10 price target. The initiation noted that although the stock trades at a discount compared with large-cap medical technology peers and its own historical valuation range, the overall risk and reward profile is considered balanced. The firm highlighted limited near-term upside potential ahead of more significant catalysts expected in 2027. It also pointed to near-term growth as being sensitive to shifts in market share and pricing dynamics, which could constrain performance relative to expectations in the short term.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) also announced on April 7 that it has appointed Jonathan M. Vigdorchik, M.D., as Chief Science, Technology, and Medical Affairs Officer, effective April 14, 2026. In this expanded leadership role, he will guide the company’s global technology strategy across artificial intelligence, robotics, smart implant systems, and data-driven solutions.

He will also oversee medical education initiatives and the company’s global advisory board, supporting stronger clinical engagement and innovation development. Dr. Vigdorchik, an orthopedic surgeon with prior experience at ZBH, brings clinical and research expertise aimed at advancing orthopedic care. His appointment is intended to strengthen the company’s innovation pipeline and accelerate the development of advanced surgical technologies.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a global medical device company specializing in orthopedic products, including joint replacement, sports medicine, and spine solutions. It develops advanced implants and surgical technologies designed to improve mobility and quality of life for patients.

According to Eli Casdin, CEO of Casdin Capital, biotech is currently experiencing a momentary stop despite being in one of the best economic environments in years. The start of this year has been more muted, despite the great performance from the previous year. However, he did note that earlier in the year, there had been a similar trend, with momentum growing. Today, there is still a lot of underground activity, including mergers and acquisitions for more than $225 billion, which has contributed to stable prices. According to Casdin, investors are currently searching for the next big opportunity while in an experimental phase.

There is a lot of hope for the future due to a significant change in the industry: by 2030, almost $200 billion in pharmaceutical revenue is anticipated to face patent expirations. Large pharmaceutical companies are under pressure to reinvest and rebuild their pipelines due to the availability of over a trillion dollars in funding, which encourages more dealmaking. Casdin also emphasized the importance of artificial intelligence, stressing that although it can speed up invention and change procedures, it cannot take the place of the biological and physical aspects of medication development. Rather, AI serves as a potent instrument that promotes innovation and increases productivity.

Investors are also paying more attention to the larger healthcare industry. After a period of underperformance due to policy concerns, it has been outperforming since the beginning of the year alongside normally protective sectors. Because healthcare is less correlated with technology and sentiment is improving, analysts predict continued upside.

This outlook is further supported by industry trends. As businesses increase their purchases in response to impending patent cliffs, biopharma is starting the year with newfound vigor. Smaller biotech companies with promising pipelines are also seeing an increase in investor confidence. Furthermore, the convergence of digital health and biotechnology is drawing additional investment, setting the industry up for long term growth and potential.

With that said, let’s view the best biotech stocks.

Our Methodology 

For our methodology, we began by screening for stocks with a closing price under $10 as of April 10 and positive upside potential. From the filtered results, we selected stocks with the most recent news and developments, and then ranked them in ascending order based on the total number of hedge fund holders as of Q4 2025, as tracked by the Insider Monkey database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Here is our list of the 10 best biotech stocks under $10 to buy.

10. MacroGenics, Inc. (NASDAQ:MGNX) 

Number of Hedge Fund Holders: 15 

Stock Price as of Last Close on April 10: $3.60

MacroGenics, Inc. (NASDAQ:MGNX) is one of the best biotech stocks.

TheFly reported on April 10 that B. Riley raised its rating on MGNX to Buy from Neutral and assigned a $9 price target. The firm highlighted the company’s positioning in the evolving antibody-drug conjugate landscape, particularly within the ADAM9 TOPO1 inhibitor segment. Its view follows recent industry developments, including a notable transaction involving Gilead, which prompted a reassessment of valuation approaches for next-generation ADC platform companies.

Separately, on April 8, MacroGenics, Inc. (NASDAQ:MGNX) announced that the U.S. Food and Drug Administration lifted the partial clinical hold on its Phase 2 LINNET trial evaluating lorigerlimab, an investigational bispecific antibody targeting PD-1 and CTLA-4. During the restriction period, patients already enrolled were permitted to continue treatment.

With the hold now removed, the company plans to restart enrollment of new participants under an updated study protocol that incorporates added safety measures to address potential blood-related and cardiac risks. The company indicated that it worked closely with regulators to resolve concerns and remains on schedule to provide a clinical update on the program later in the year, as development of the therapy continues.

MacroGenics, Inc. (NASDAQ:MGNX) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. It leverages proprietary technologies to create targeted treatments designed to enhance immune response and improve outcomes for patients with unmet medical needs.

9. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) 

Number of Hedge Fund Holders: 21 

Stock Price as of Last Close on April 10: $8.00

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is one of the best biotech stocks on this list.

TheFly reported on April 7 that RBC Capital reduced its price target on KPTI to $16 from $23 while maintaining an Outperform rating. The revision was part of a broader biotech sector preview ahead of first-quarter results. The firm noted potential short-term pressures from seasonal dynamics, reimbursement resets, fewer selling days, and weather-related disruptions, particularly affecting newly launched and clinic-administered products. Despite these challenges, it highlighted that renewed merger and acquisition activity, along with improved visibility on pricing and tariff-related factors, could help support sentiment and offset broader macroeconomic uncertainty within the sector.

Moreover, earlier on March 24, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) entered into a securities purchase agreement with RA Capital Management for a private financing expected to generate approximately $30 million in gross proceeds, with potential for additional funds if associated warrants are exercised.

The transaction includes the sale of common stock, pre-funded warrants, and accompanying warrants, with closing anticipated later in the month, subject to customary conditions. The company plans to use the proceeds to support general corporate activities, including advancing its clinical development programs. Combined with existing resources, the funding is expected to sustain operations into the third quarter of 2026.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage biopharmaceutical company focused on developing and commercializing novel cancer therapies. It specializes in selective inhibitors of nuclear export (SINE) to treat hematologic malignancies and solid tumors.

5. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Number of Hedge Fund Holders: 28 

Stock Price as of Last Close on April 10: $9.80

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is among the best biotech stocks.

TheFly reported on April 7 that Mizuho raised its price target on CRBP from $39 to $40 while maintaining an Outperform rating. The firm updated its valuation model following the company’s fourth quarter results. The corporation is expected to deliver three clinical data readouts during 2026, which the firm views as key upcoming catalysts. Mizuho also noted that the stock is currently trading near the company’s cash position, suggesting limited downside and an attractive risk-reward profile ahead of multiple potential data-driven events.

Additionally, on April 7, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced it has reached broad alignment with the U.S. FDA on the registration strategy for CRB-701, a next-generation Nectin-4 targeting antibody-drug conjugate being developed for head and neck squamous cell carcinoma and cervical cancer.

The planned registrational approach includes separate randomized controlled studies in each indication comparing CRB-701 to standard chemotherapy regimens, with objective response rate as the basis for potential accelerated approval and overall survival as the confirmatory endpoint for full approval. The company will continue discussions with the FDA to finalize study protocols and statistical analysis plans. In addition, Corbus disclosed a leadership change, with its chief medical officer stepping down effective June 30, 2026.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for inflammatory and fibrotic diseases. It is also expanding into oncology, aiming to create targeted treatments that modulate the immune system and improve patient outcomes.

In December, CNBC reported that health-care job growth is propping up the labor market at a time when many other industries are struggling. Labor economists see this as a worrying signal for job seekers and the broader US economy. Employers in the health care and social services sector added 695,000 jobs in 2025 through November, based on data from the US Bureau of Labor Statistics. At the same time, total job gains across the U.S. economy reached 610,000. That gap stands out, as without hiring in health care, the economy would have lost about 85,000 jobs.

The J.P. Morgan 44th Annual Healthcare Conference offered a clearer sense of what may lie ahead for the industry. Discussions at the conference showed that researchers are continuing to find benefits for GLP-1s beyond weight loss. Data points to their ability to help prevent diabetes and reduce cardiovascular risks.

Several industry and government leaders described GLP-1s as a “strategic investment” in addressing health risks linked to obesity. There is also a broader implication. Expanding access to these drugs could reduce chronic noncommunicable diseases in obese populations, which may lower overall healthcare utilization. At the same time, the Trump administration said it had brokered a deal to lower GLP-1 prices for Medicare and Medicaid recipients. This could support wider use, especially as a GLP-1 pill enters the market.

Taken together, these developments suggest that demand for GLP-1s will grow, and competition among manufacturers is likely to intensify.

Given this, we will take a look at some of the best healthcare stocks with the highest dividends.

Our Methodology:

For this list, we screened for dividend stocks within the healthcare sector and picked those with dividend yields above 2%, as of April 15. These stocks are also popular among hedge funds. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10. Elevance Health, Inc. (NYSE:ELV)

Dividend Yield as of April 15: 2.2%

On April 13, Truist lowered its price recommendation on Elevance Health, Inc. (NYSE:ELV) to $375 from $390. It reiterated a Buy rating on the shares. The change came as part of a broader Q1 preview for Healthcare Services. The firm still takes a positive view on the sector. It points to steady demand, long-term structural tailwinds, and a reimbursement environment that looks more stable. The recent Final Medicare Advantage Rule was described as an “encouraging data point,” according to the analyst. Truist also noted that the group benefits from its scale and domestic focus. It sees the sector as defensive in nature. At the same time, companies are gaining from AI, automation, and better connectivity across systems. Strong free cash flow and financial flexibility are expected to support continued investment, M&A activity, and shareholder returns.

On April 8, Evercore ISI analyst Elizabeth Anderson initiated coverage of Elevance Health with an In Line rating and a $345 price target. The firm described Elevance as a diversified managed care company with “resilient” earnings in the current environment. It suggested the company could meet or exceed its 2026 guidance. Still, there are some concerns. Evercore sees downside risk to 2027 estimates. It also flagged a “meaningful likelihood” that the One Big Beautiful Bill work requirements could trigger “another wave of rate-acuity mismatch” in Medicaid.

Elevance Health, Inc. (NYSE:ELV) operates as a health insurer in the United States. The business is organized into four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

9. Johnson & Johnson (NYSE:JNJ)

Dividend Yield as of April 15: 2.25%

On April 15, Barclays analyst Matt Miksic raised the firm’s price recommendation on Johnson & Johnson (NYSE:JNJ) to $255 from $234. It reiterated an Equal Weight rating on the shares. The analyst noted that the company’s pharma unit delivered its sixth consecutive quarter of double-digit organic growth. In a research note, Barclays said it expects J&J’s new products, along with “durable” core growth in medical technology and pharma, to support its goal of double-digit sales growth by the end of the decade.

During the Q1 2026 earnings call, CEO and Chairman Joaquin Duato said the company delivered operational sales growth of 6.4%. He explained that the company’s growth strategy remains focused on oncology, immunology, neuroscience, cardiovascular, surgery, and vision. He also said the company now has 28 platforms or products generating at least $1 billion in annual revenue and is on track to reach its 2026 target of $100 billion in annual revenue for the first time.

Speaking about oncology, Duato said DARZALEX continues to serve as the gold standard in multiple myeloma, with sales of $4 billion and operational sales growth of 18%. He also pointed to the FDA approval of TECVAYLI in combination with DARZALEX FASPRO, noting that the regimen could position itself as a potential new standard of care as early as the second-line setting.

Johnson & Johnson (NYSE:JNJ) and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech.

5. Amgen Inc. (NASDAQ:AMGN)

Dividend Yield as of April 15: 2.89%

On April 13, UBS lifted its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $400 from $390. It reiterated a Buy rating on the shares. The revision came as part of a broader Q1 preview across the pharmaceuticals and biotechnology group.

On April 8, Truist also updated its view on the company. It boosted its price target to $325 from $319 and maintained a Hold rating, as part of a wider preview of Q1 earnings in biotech. The firm said that reactivity to regulatory and policy shifts across the sector has started to ease. It also pointed to a recent pickup in deal activity, which could build momentum through the rest of the year and into the mid-term period. For Amgen, Truist made a few specific adjustments. It increased its long-term penetration assumptions for Krystexxa, citing stronger patent protection that now extends into 2040. It also raised the probability of success for MariTide, reflecting greater confidence in its commercially viable profile in obesity.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company focused on discovering, developing, manufacturing, and delivering medicines for serious diseases. The company targets areas with high unmet medical needs and uses its expertise to develop treatments aimed at improving patient outcomes. It operates within the human therapeutics segment.

D-Wave Quantum soared for a 4th straight session on Wednesday, climbing 22.51 percent to finish at $20.79 apiece, as investors took heart from Nvidia Corp.’s development of two new products aimed at solving the challenges of the quantum computing sector.

D-Wave Quantum Computing Inc. (NYSE:QBTS) climbed alongside its counterparts Rigetti, IonQ, and Infleqtion, among others, following Nvidia’s launch of a new AI-powered workflow designed to correct quantum systems’ biggest problems.

Photo from D-Wave website

Called the Ising Calibration and Ising Decoding, Nvidia said that the two model domains can both target the fundamental challenges in quantum computing.

Ising Calibration is a vision-language model for automating QPU calibration tasks capable of understanding quantum computing scientific experiment output and how it compares to expected trends, while Ising Decoding consists of two 3D CNN models for demanding decoding needed during quantum error correction.

Investors took the development positively, sparking appetite for key players, including D-Wave Quantum Computing Inc. (NYSE:QBTS), as it validated the increasing importance of the quantum sector after executives from technology giants earlier said that they deem the industry useful only decades away.

Also on Wednesday, investors loaded portfolios on expectations of business updates from CEO Alan Baratz, who participated in the QED-C Quantum Summit on the same day.

[im-yf-promo]

While we acknowledge the potential of QBTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

IonQ extended its winning streak to a 4th straight session on Wednesday, surging 20.92 percent to end at $43.24 apiece, thanks to Nvidia Corp.’s launch of two new models supporting the challenges of the quantum computing sector.

Earlier this week, Nvidia launched what it called the “Ising” Calibration and Decoding models, which aim to solve fundamental challenges in the quantum computing sector.

For illustration purposes only. Photo by Tima Miroshnichenko on Pexels

Ising Calibration is a vision-language model for automating QPU calibration tasks, which is capable of understanding quantum computing scientific experiment output and how it compares to expected trends, while Ising Decoding consists of two 3D CNN models for demanding decoding needed during quantum error correction.

Investors took the unveiling positively, sparking appetite for key players, including IonQ Inc. (NASDAQ:IONQ), as the development not only addressed major challenges being faced by the sector but also validated the industry’s relevance, countering earlier views that its practical use was still decades away.

In other news, IonQ Inc. (NASDAQ:IONQ) said that it would release the results of its earnings performance in the first quarter of the year after market close on May 6, 2026. A conference call will be held to elaborate on the results.

Earlier this week, IonQ Inc. (NASDAQ:IONQ) also announced a new milestone photonically interconnecting two independent trapped-ion quantum systems, bolstering its targets of moving to distributed, networked architectures from individual quantum processors at present.

“Scaling quantum computation beyond the limits of a single chip is essential for realizing a future quantum internet. This demonstration proves that our trapped-ion platform is uniquely suited for the high-fidelity networking required to solve the world’s most complex problems,” CEO Niccolo de Masi said.

[im-yf-promo]

While we acknowledge the potential of IONQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

Quantum Computing surged by 15.91 percent on Wednesday to close at $9.40 apiece, as investor sentiment was boosted by Nvidia Corp.’s launch of a new AI-powered workflow designed to correct quantum systems’ biggest problems.

Nvidia unveiled what it called the “Ising” Calibration and Decoding models, which aim to solve fundamental challenges in quantum computing.

Photo by Jeremy Waterhouse on Pexels

Ising Calibration is a vision-language model for automating QPU calibration tasks, which is capable of understanding quantum computing scientific experiment output and how it compares to expected trends, while Ising Decoding consists of two 3D CNN models for demanding decoding needed during quantum error correction.

Investors took the unveiling positively, sparking appetite for key players, including Quantum Computing Inc. (NASDAQ:QUBT), as the development not only addressed major challenges being faced by the sector but also validated the industry’s relevance, countering earlier views that its practical use was still decades away.

In other news, Quantum Computing Inc. (NASDAQ:QUBT) last month announced impressive financial and operating performance for the full-year 2025 period, with net losses shrinking by 73 percent to $18.67 million from $68.5 million in 2024. Revenues soared by 83 percent to $682 million from $373 million year-on-year.

In the fourth quarter alone, Quantum Computing Inc. (NASDAQ:QUBT) nearly wiped its net losses, slashing them by 97 percent to $1.556 million from $51.237 million in the same quarter a year earlier. Revenues also increased by 219 percent to $198 million from $62 million year-on-year.

[im-yf-promo]

While we acknowledge the potential of QUBT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

Tempus AI extended its winning streak to a 3rd straight session on Wednesday, surging 13.89 percent to close at $56.41 apiece, as investors took heart from the official launch of a new test kit capable of detecting cancer from a blood sample alone.

In an updated report, Tempus AI Inc. (NASDAQ:TEM) said that it partnered with Predicta Biosciences—a precision oncology company—for the launch of the GenoPredicta test kit, which can extract deep insights from a blood sample or bone marrow with as few as 50 cancer cells.

Photo from Tempus AI website

Tempus AI Inc. (NASDAQ:TEM) said that the test kit is so sensitive that it can track cancer even in individuals who previously did not have enough detectable cancer cells for analysis.

The test kit would support medical practitioners and researchers in the accurate diagnosis of cancer, in figuring out how severe the disease is, identifying if drugs or therapies work, and tracking for cancer cells left after treatment.

“GenoPredicta offers a novel, unified solution for our life science partners and a comprehensive replacement for traditional, siloed testing,” Tempus AI Inc. (NASDAQ:TEM) Chief Scientific Officer Kate Sasser said.

“By consolidating flow cytometry, cytogenetics, and WGS into one ultrasensitive workflow, we can identify high-risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100 percent concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies,” she noted.

[im-yf-promo]

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

Aurora Innovation extended its winning streak to a 4th consecutive day on Wednesday, jumping 13.49 percent to close at $5.30 apiece, as investors resumed buying positions ahead of the results of its first quarter earnings performance.

In a notice to investors, Aurora Innovation Inc. (NASDAQ:AUR) said that it would release its financial and operating highlights for the period after market close on May 6, 2026. A conference call will be held to discuss the results.

Photo from Aurora Innovation website

Investors are also expected to closely watch for the company’s updated outlook for the year, with an earlier target of more than 200 driverless trucks in operation by the end of 2026.

According to Aurora Innovation Inc. (NASDAQ:AUR), the said fleet expansion would support its goal of a “multi-fold increase” in revenues, with an exit rate that will generate financial momentum heading into 2027.

Aurora Innovation Inc. (NASDAQ:AUR) is a US-based company engaged in autonomous driving, which began earning revenues only last year.

During the period, it was able to rake in $3 million in revenues, while net loss widened by 9 percent to $816 million from $748 million in 2024.

In the fourth quarter alone, it generated $1 million in revenues versus none in the same period in 2024. Net loss grew by 6.7 percent to $206 million from $193 million year-on-year.

[im-yf-promo]

While we acknowledge the potential of AUR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

Rigetti Computing grew for a 4th consecutive day on Wednesday, jumping 13.28 percent to finish at $19.11 apiece, as investors resumed buying positions following Nvidia Corp.’s launch of a new AI-powered workflow designed to correct quantum systems’ biggest problems.

Nvidia earlier this week unveiled what it called the “Ising” Calibration and Decoding—two model domains targeting the fundamental challenges in quantum computing.

Photo by Sergei Starostin on Pexels

Ising Calibration is a vision-language model for automating QPU calibration tasks, which is capable of understanding quantum computing scientific experiment output and how it compares to expected trends, while Ising Decoding consists of two 3D CNN models for demanding decoding needed during quantum error correction.

Investors took the unveiling positively, sparking appetite for key players, including Rigetti Computing Inc. (NASDAQ:RGTI), as the development not only addressed major challenges being faced by the sector, but also validated the industry’s relevance, countering earlier views that its practical use was still decades away.

In other news, Rigetti Computing Inc. (NASDAQ:RGTI) announced the general availability of its new 108-qubit quantum computing system, Cepheus-1-108Q, on Rigetti Quantum Cloud Services (QCS) Platform and Amazon Braket.

Cepheus-1-108Q is Rigetti’s highest qubit-count system to date and the industry’s largest modular quantum computing system, based on Rigetti’s proprietary chiplet-based architecture. The system comprises twelve interconnected 9-qubit chiplets, tripling the number of qubits and chiplets from Rigetti’s previous 36-qubit system, Cepheus-1-36Q.

The system is currently performing at a 99.1% median two-qubit gate fidelity with a gate speed of ~60 ns and a 99.9% median single-gate fidelity.

Rigetti Computing Inc. (NASDAQ:RGTI) said that it is releasing Cepheus-1-108Q now in response to growing customer interest and will continue to improve the system performance throughout 2026 as the company advances on its roadmap.

[im-yf-promo]

While we acknowledge the potential of RGTI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

Cheniere Energy Partners, L.P. (NYSE:CQP) provides clean, secure, and affordable LNG to integrated energy companies, utilities, and energy trading companies around the world.

On April 2, Citi analyst Spiro Dounis bumped the firm’s price target on Cheniere Energy Partners, L.P. (NYSE:CQP) from $49 to $55, but maintained a ‘Sell’ rating on the shares. The raised target still indicates a downside of over 11% from the current share price.

The analyst firm pointed to the disruptions in the Middle East for the update, which it believes could have a lasting positive impact on the US LNG industry in the long run. The US-Iran war has choked around a fifth of the global LNG supply, forcing customers (especially in the Asian markets) to look for alternatives. As a result, the US LNG shipments to Asia soared to 1.99 million tons in March, more than twice the 970,000 tons shipped in February, according to data from LSEG.

Moreover, an Iranian missile attack on QatarEnergy forced the company to halt LNG ⁠production last month. The industry giant has warned that the outage could remove over 12 million mtpa of supply for up to five years, presenting a significant opportunity for American suppliers.

[im-yf-promo]

While we acknowledge the potential of CQP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 15 Best American Energy Stocks to Buy According to Wall Street Analysts and 15 Best Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.

Upstart Holdings rallied for a 3rd straight day on Wednesday, climbing 12.97 percent to close at $33.36 apiece, as investors began loading positions ahead of the results of its first-quarter earnings performance.

In a notice on its website, Upstart Holdings Inc. (NASDAQ:UPST) said that it would release its financial and operating highlights before market open on May 6, 2026, to be complemented by a conference call to discuss the results.

For illustration purposes only. Photo by Ketut Subiyanto on Pexels

Last February, Upstart Holdings Inc. (NASDAQ:UPST) said that it would discontinue issuing quarterly business outlooks and focus on annual guidance instead. For this year alone, total revenues are targeted to grow by 40 percent to $1.4 billion from $1 billion in 2025.

Revenues from fees are expected to be $1.3 billion, or an implied growth of 36.8 percent from the $950 million last year.

In other developments, Upstart Holdings Inc. (NASDAQ:UPST) is currently facing a lawsuit over the collapse of its conversion rate to 20.6 percent in the third quarter last year from 23.9 percent the quarter prior, which directly reduced loan origination volume and allegedly caused the company to miss its own quarterly revenue guidance by $3 million.

Shareholder law firms are luring investors who purchased shares of the company between May 14 and November 4 of last year to apply as lead plaintiff for the lawsuit by the June 8, 2026 deadline.

[im-yf-promo]

While we acknowledge the potential of UPST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

Pembina Pipeline Corporation (NYSE:PBA) is a leading energy transportation and midstream service provider that has been serving North America’s energy industry for 70 years.

On April 8, BMO Capital upped its price target on Pembina Pipeline Corporation (NYSE:PBA) from C$60 to C$63, while maintaining a ‘Market Perform’ rating on the shares. The revised target reflects an upside potential of almost 4% from the current share price.

The move comes following an April 7 announcement by Pembina Pipeline Corporation (NYSE:PBA) that it expects to deliver 5% to 7% compound annual fee-based adjusted EBITDA per share growth through 2030. The outlook is supported by the company’s higher utilization of existing assets and ​contributions from sanctioned new projects entering service. The guidance represents a step-up of around 100 basis points from the midstream operator’s prior 2024-26 growth target.

Pembina Pipeline Corporation (NYSE:PBA) also revealed that it had entered into incremental hedges for ​2026. According to the company, around 65% of ​its 2026 frac spread exposure is currently hedged, with ‌around ⁠40% hedged in Q1 and Q4 and about 90% in the second and third quarters.

Pembina Pipeline Corporation (NYSE:PBA)’s long-term goals beyond 2030 include continued investments in the core business to keep up with the rising demand, as well as additional investments in LNG, LPG, gas-to-power, and emissions reduction infrastructure.

[im-yf-promo]

While we acknowledge the potential of PBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 15 Best American Energy Stocks to Buy According to Wall Street Analysts and 15 Best Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.

Kinetik Holdings Inc. (NYSE:KNTK) is the premier midstream operator in the Delaware Basin, providing gathering, compression, processing, transportation, and water management services.

On April 10, Barclays bumped its price target on Kinetik Holdings Inc. (NYSE:KNTK) from $44 to $46, while maintaining an ‘Equal’ Weight rating on the shares.

The analyst noted that while Kinetik Holdings Inc. (NYSE:KNTK)’s 2026 earnings are still weighted towards the latter half of the year, the stock’s outlook is becoming more favorable. Barclays believes that the higher energy prices amid the Middle East conflict, the growth in volumes, and its upcoming projects position Kinetik to improve its results as the year unfolds.

Kinetik Holdings Inc. (NYSE:KNTK) is targeting an adjusted EBITDA in the range of $950 million to $1.05 billion in FY 2026, indicating a YoY growth of over 7% at the midpoint when adjusted for the sale of EPIC Crude. The company also reiterated its commitment to shareholders by announcing its target of “annual dividend increases of 3% to 5% until dividend coverage reaches 1.6x, and leverage between 3.5x and 4x.”

With a robust annual dividend yield of 6.86%, Kinetik Holdings Inc. (NYSE:KNTK) was recently included in our list of the 13 Oil Stocks with Highest Dividends.

[im-yf-promo]

While we acknowledge the potential of KNTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 15 Best American Energy Stocks to Buy According to Wall Street Analysts and 15 Best Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.

Figma rallied by 10.39 percent on Wednesday to close at $20.33 apiece, with the rally primarily driven by an overall market optimism and renewed confidence for AI-related stocks that overshadowed news of key management changes.

In a regulatory filing, Figma Inc. (NYSE:FIG) announced that Mike Krieger, who joined the company last year, has stepped down from the board effective immediately.

Photo from Figma website

The company did not divulge any reason for the resignation, but it dispelled any disagreement with the management or its policies.

Earlier this week, Figma Inc. (NYSE:FIG) received a “neutral” rating from investment firm BTIG, reflecting its mixed outlook for its future performance, particularly over concerns about valuation and path to profitability despite the listed firm’s revenue growth expectations.

BTIG said that it remained neutral about the listed firm’s potential to be one of the earliest application software companies to monetize AI, despite the latter already beginning to generate revenues from credit consumption and credit limits from its AI-powered tool, Make, and in spite of a 70-percent increase in weekly average users quarter-on-quarter.

“That said, it remains difficult to decipher the degree to which monetization can happen in the [near term] and how much the initial usage will carry through once customers are charged,” it noted.

[im-yf-promo]

While we acknowledge the potential of FIG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

NGL Energy Partners LP (NYSE:NGL) is a diversified midstream MLP that provides multiple services to producers and end-users, including transportation, storage, blending, and marketing of crude oil, NGLs, refined products/renewables, and water solutions.

NGL Energy Partners LP (NYSE:NGL) announced on April 9 that its Board of Directors had authorized a share repurchase program of up to $100 million. The program allows the company to buy back its outstanding units on a discretionary basis from time to time through open market transactions or privately negotiated transactions at prices it deems appropriate. The authorization does not have a fixed expiration date.

NGL Energy Partners LP (NYSE:NGL) revealed in its last earnings call in February that it had almost fully exhausted its board-approved common unit repurchase plan. The company bought back 1.6 million shares of its common stock during Q3 2026, bringing the total repurchases of its last program to approximately 8.7 million shares since inception. This was equivalent to almost 7% of the NGL’s total outstanding shares at the time.

[im-yf-promo]

While we acknowledge the potential of NGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 15 Best American Energy Stocks to Buy According to Wall Street Analysts and 15 Best Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.

Image by Alexsander-777 from Pixabay

Plains GP Holdings, L.P. (NASDAQ:PAGP) owns and operates midstream infrastructure systems in the United States and Canada. It operates through Crude Oil and Natural Gas Liquids (NGLs) segments.

On April 10, Barclays raised its price target on Plains GP Holdings, L.P. (NASDAQ:PAGP) from $18 to $21, but kept its ‘Underweight’ rating on the shares. That said, the increased target still indicates a downside of over 12% from the current levels.

The move comes as Barclays sees long-term growth prospects for Plains GP Holdings, L.P. (NASDAQ:PAGP), driven by the structurally higher crude prices amid the US-Iran conflict, as well as the increased production activity in the United States.

Similarly, the analysts over at Truist and Morgan Stanley have also turned more bullish on Plains GP Holdings, L.P. (NASDAQ:PAGP) and recently raised their respective price targets on the stock (read more details here).

In other news, Plains GP Holdings, L.P. (NASDAQ:PAGP) announced a quarterly dividend of $0.4175 per share on April 8. The dividend is payable on May 15 to all shareholders of record May 1, 2026. The stock currently has a strong annual dividend yield of 7.08%.

[im-yf-promo]

While we acknowledge the potential of PAGP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 15 Best American Energy Stocks to Buy According to Wall Street Analysts and 15 Best Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.

Venture Global, Inc. (NYSE:VG) develops and constructs LNG export projects to provide clean, affordable energy to the world. The company is currently one of the largest LNG exporters in the United States.

On April 14, JPMorgan analyst Jeremy Tonet trimmed the firm’s price target on Venture Global, Inc. (NYSE:VG) from $19 to $16, while keeping a ‘Neutral’ rating on the shares. The lowered target, which still indicates an upside of almost 28% from the current levels, comes as the analyst firm updated the company’s model ahead of the upcoming Q1 report.

While JP Morgan expects Venture Global, Inc. (NYSE:VG) to be weighed down by dislocations, it expects the high spot LNG prices to lift the company’s earnings this year. The Strait of Hormuz blockade has choked around 20% of the global LNG supply. Moreover, the Iranian attack on QatarEnergy forced it to halt LNG ⁠production last month, with the company warning that the outage could remove over 12 million mtpa of supply for up to five years. The supply disruptions have sent the spot LNG prices soaring, especially in Asia, where buyers are now looking for alternatives.

Venture Global, Inc. (NYSE:VG) is targeting a consolidated EBITDA in the range of $5.2 billion to $5.8 billion for FY 2026.

[im-yf-promo]

While we acknowledge the potential of VG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 15 Best American Energy Stocks to Buy According to Wall Street Analysts and 15 Best Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.